These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

303 related items for PubMed ID: 18033780

  • 21. Time-kill synergy tests of tigecycline combined with imipenem, amikacin, and ciprofloxacin against clinical isolates of multidrug-resistant Klebsiella pneumoniae and Escherichia coli.
    Yim H, Woo H, Song W, Park MJ, Kim HS, Lee KM, Hur J, Park MS.
    Ann Clin Lab Sci; 2011; 41(1):39-43. PubMed ID: 21325253
    [Abstract] [Full Text] [Related]

  • 22. Update on antimicrobial susceptibility rates among gram-negative and gram-positive organisms in the United States: results from the Tigecycline Evaluation and Surveillance Trial (TEST) 2005 to 2007.
    Dowzicky MJ, Park CH.
    Clin Ther; 2008 Nov; 30(11):2040-50. PubMed ID: 19108792
    [Abstract] [Full Text] [Related]

  • 23. In vitro activities of 'new' and 'conventional' antibiotics against multi-drug resistant Gram negative bacteria from patients in the intensive care unit.
    Ratnam I, Franklin C, Spelman DW.
    Pathology; 2007 Dec; 39(6):586-8. PubMed ID: 18027263
    [Abstract] [Full Text] [Related]

  • 24. Tigecycline.
    Pankey GA.
    J Antimicrob Chemother; 2005 Sep; 56(3):470-80. PubMed ID: 16040625
    [Abstract] [Full Text] [Related]

  • 25. Tigecycline: an investigational glycylcycline antimicrobial with activity against resistant gram-positive organisms.
    Garrison MW, Neumiller JJ, Setter SM.
    Clin Ther; 2005 Jan; 27(1):12-22. PubMed ID: 15763603
    [Abstract] [Full Text] [Related]

  • 26. In vitro activity of cefepime, imipenem, tigecycline, and gentamicin, alone and in combination, against extended-spectrum beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli.
    Cha R.
    Pharmacotherapy; 2008 Mar; 28(3):295-300. PubMed ID: 18294108
    [Abstract] [Full Text] [Related]

  • 27. Comparative bactericidal activities of daptomycin, glycopeptides, linezolid and tigecycline against blood isolates of Gram-positive bacteria in Taiwan.
    Huang YT, Liao CH, Teng LJ, Hsueh PR.
    Clin Microbiol Infect; 2008 Feb; 14(2):124-9. PubMed ID: 18076671
    [Abstract] [Full Text] [Related]

  • 28. In vitro evaluation of tigecycline and comparative agents in 3049 clinical isolates: 2001 to 2002.
    Bouchillon SK, Hoban DJ, Johnson BM, Stevens TM, Dowzicky MJ, Wu DH, Bradford PA.
    Diagn Microbiol Infect Dis; 2005 Apr; 51(4):291-5. PubMed ID: 15808321
    [Abstract] [Full Text] [Related]

  • 29. Antimicrobial activity of tigecycline against bacterial isolates from intensive care units in a teaching hospital in Central Saudi Arabia.
    Somily AM, Al-Khattaf AS, Kambal AM.
    Saudi Med J; 2010 Jan; 31(1):18-24. PubMed ID: 20062893
    [Abstract] [Full Text] [Related]

  • 30. Inhibitory effect of Gram-negative and Gram-positive microorganisms against Helicobacter pylori clinical isolates.
    López-Brea M, Alarcón T, Domingo D, Díaz-Regañón J.
    J Antimicrob Chemother; 2008 Jan; 61(1):139-42. PubMed ID: 17965421
    [Abstract] [Full Text] [Related]

  • 31. Tigecycline in-vitro susceptibility and antibiotics' fitness for gram-negative pathogens.
    Arya SC, Agarwal N.
    Saudi Med J; 2008 Nov; 29(11):1558-60. PubMed ID: 18998000
    [Abstract] [Full Text] [Related]

  • 32. Antimicrobial susceptibility among organisms from the Asia/Pacific Rim, Europe and Latin and North America collected as part of TEST and the in vitro activity of tigecycline.
    Reinert RR, Low DE, Rossi F, Zhang X, Wattal C, Dowzicky MJ.
    J Antimicrob Chemother; 2007 Nov; 60(5):1018-29. PubMed ID: 17855724
    [Abstract] [Full Text] [Related]

  • 33. A longitudinal analysis of antimicrobial susceptibility in clinical institutions in Germany as part of the Tigecycline Evaluation and Surveillance Trial (2004-2007).
    Seifert H, Dowzicky MJ.
    Chemotherapy; 2009 Nov; 55(4):241-52. PubMed ID: 19468222
    [Abstract] [Full Text] [Related]

  • 34. Tigecycline in vitro activity against commonly encountered multidrug-resistant gram-negative pathogens in a Middle Eastern country.
    Araj GF, Ibrahim GY.
    Diagn Microbiol Infect Dis; 2008 Dec; 62(4):411-5. PubMed ID: 18814990
    [Abstract] [Full Text] [Related]

  • 35. Comparison of 2002-2006 OPTAMA programs for US hospitals: focus on gram-negative resistance.
    Crandon JL, Kuti JL, Jones RN, Nicolau DP.
    Ann Pharmacother; 2009 Feb; 43(2):220-7. PubMed ID: 19193582
    [Abstract] [Full Text] [Related]

  • 36. Comparative activity of tigecycline and tetracycline on Gram-negative and Gram-positive bacteria revealed by a multicentre study in four North European countries.
    Nilsson LE, Frimodt-Møller N, Vaara M, Simonsen GS, Tigecycline Study Group.
    Scand J Infect Dis; 2011 Sep; 43(9):707-13. PubMed ID: 21619494
    [Abstract] [Full Text] [Related]

  • 37. In vitro activities of tigecycline against clinical isolates from Shanghai, China.
    Zhang YY, Zhou L, Zhu DM, Wu PC, Hu FP, Wu WH, Wang F.
    Diagn Microbiol Infect Dis; 2004 Dec; 50(4):267-81. PubMed ID: 15582300
    [Abstract] [Full Text] [Related]

  • 38. In vitro antibacterial activity of tigecycline against resistant Gram-negative bacilli and enterococci by time-kill assay.
    Pankey GA, Ashcraft DS.
    Diagn Microbiol Infect Dis; 2009 Jul; 64(3):300-4. PubMed ID: 19501791
    [Abstract] [Full Text] [Related]

  • 39. In vitro activity of tigecycline against resistant micro-organisms isolated from burn patients.
    Timurkaynak F, Arslan H, Azap OK, Senger SS, Başaran O, Karaman SO, Haberal M.
    Burns; 2008 Nov; 34(7):1033-6. PubMed ID: 18539397
    [Abstract] [Full Text] [Related]

  • 40. In vitro activity of tigecycline and comparators against gram-negative bacteria isolated from a tertiary hospital in Alexandria, Egypt.
    Mohamed NM, Youssef AA.
    Microb Drug Resist; 2011 Dec; 17(4):489-95. PubMed ID: 21875338
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 16.